Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00242723 · ClinicalTrials.gov registry record
Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
A clinical trial of Thoracic Cancers and Malignant Pleural Mesotheliomas NOS, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- 1,310
- Enrollment target
- 1
- Study location
NCT00242723: Recruiting study of Thoracic Cancers and Malignant Pleural Mesotheliomas NOS, sponsored by National Cancer Institute (NCI).
NCT00242723 is a study of Thoracic Cancers and Malignant Pleural Mesotheliomas NOS that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 1,310 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00242723, a study of Thoracic Cancers and Malignant Pleural Mesotheliomas NOS, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- 1,310 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: * Chromatin is is the structural building block of a chromosome. It is found inside the nucleus of the cell and consists of a complex of DNA and protein. * Cancers of the lung, pleura (lung lining) and esophagus show profound changes in chromatin structure that may affect the course of disease in patients. * A better understanding of these diseases and the genetic changes associated with them may be helpful in developing new treatments for them. Objectives: * To evaluate people with cancer of the lung, pleura or esophagus for participation in NCI clinical trials. * To obtain biopsies (small pieces of tissue) from tumor, normal tissue and blood samples to learn more about the cellular changes in blood and tissue in tumors of the lung, esophagus and pleura and surrounding structures in the chest. Eligibility: Patients 2 years of age and older with cancer of the lung, esophagus, pleura, mediastinum or chest wall, or cancers of other origin that have invaded the lung. Note: Patients \>= 2 years of age and under 18 years of age may only participate in research sample collection. Design: * Up to 1310 patients may be included in this study. * Patients undergo standard tests for evaluating the stage of their disease and for determining eligibility for an NCI investigational treatment study. * All patients undergo bronchoscopy and bronchoalveolar lavage ("washing" with salt water) to assess their tumor and collect a sample of normal tissue. Patients whose tumor is located on the outside portion of the lung may also undergo thoracoscopy to obtain a tumor sample. For bronchoscopy and bronchoalveolar lavage a tube with a light is passed through the nose or mouth into the lungs to examine the airways. Salt water is injected through the tube and then withdrawn to obtain cells for laboratory studies. For the thoracoscopy a small tube with a light is put through a small hole in the chest to obtain the tumor sample. Both procedures are usually done under general an
Primary Outcome
Long-term follow-up visits at intervals based on participant's clinical status, to include history and medical exam, collection of research blood and urine; additional tissue from clinically indicated surgery/biopsy may be collected if available
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,310 participants |
| Start Date | 2005-11-09 |
What NCT00242723 shows while recruiting
NCT00242723 is an observational study that tracks outcomes without assigning an intervention. Its 1,310 participants enrollment target places it among the larger protocols in the corpus.
The record links to 5 conditions, with Thoracic Cancers appearing as the primary indexed condition, and to 0 interventions.
NCT00242723 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00242723 about?
NCT00242723 is a clinical study titled "Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining". Background: * Chromatin is is the structural building block of a chromosome. It is found inside the nucleus of the cell and consists of a complex of DNA and protein. * Cancers of the lung, pleura (lung lining) and esophagus show profound changes in chromatin structure that may affect the course of ...
What is the current status of trial NCT00242723?
This trial is currently recruiting. The enrollment target is 1,310 participants. The study started on 2005-11-09.
What conditions does trial NCT00242723 study?
This clinical trial studies the following conditions: Thoracic Cancers, Malignant Pleural Mesotheliomas NOS, Esophageal Cancers NOS, Lung Cancer NOS, Cancers of Non Thoracic Origin With Metastases to the Lungs or Pleura.
Who is sponsoring clinical trial NCT00242723?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00242723 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thoracic Cancers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06136624 · 1,310 participants · Phase 3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- NCT06556433 · 1,312 participants · NA
Family-Based Financial Incentives Intervention for Smoking Cessation
- NCT05176483 · 1,314 participants · Phase 1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
- NCT06136650 · 1,314 participants · Phase 3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI